Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.61 USD | +0.09% |
|
-0.34% | +12.18% |
15/07 | Baird Adjusts Medtronic Price Target to $94 From $92, Maintains Neutral Rating | MT |
15/07 | Mizuho Securities Adjusts Medtronic Price Target to $100 From $98, Maintains Outperform Rating | MT |
Fiscal Period: April | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.72 | 4.63 | 3.9 | 4.43 | 4.41 | |||||
Return on Total Capital | 4.4 | 5.44 | 4.59 | 5.22 | 5.19 | |||||
Return On Equity % | 7.08 | 9.7 | 7.25 | 7.26 | 9.51 | |||||
Return on Common Equity | 7.06 | 9.69 | 7.22 | 7.23 | 9.49 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 65.62 | 68.53 | 65.98 | 65.73 | 65.39 | |||||
SG&A Margin | 33.05 | 31.65 | 32.35 | 31.46 | 32.05 | |||||
EBITDA Margin % | 27.14 | 30.07 | 26.82 | 27.98 | 27.17 | |||||
EBITA Margin % | 24.09 | 26.99 | 23.62 | 25.03 | 24.03 | |||||
EBIT Margin % | 18.17 | 21.52 | 18.19 | 19.8 | 19.09 | |||||
Income From Continuing Operations Margin % | 12.05 | 15.97 | 12.12 | 11.44 | 13.99 | |||||
Net Income Margin % | 11.97 | 15.9 | 12.03 | 11.36 | 13.9 | |||||
Net Avail. For Common Margin % | 11.97 | 15.9 | 12.03 | 11.36 | 13.9 | |||||
Normalized Net Income Margin | 9.33 | 13.04 | 12.37 | 11.83 | 12.03 | |||||
Levered Free Cash Flow Margin | 15.86 | 15.88 | 12.53 | 16.87 | 12.54 | |||||
Unlevered Free Cash Flow Margin | 17.78 | 16.97 | 13.7 | 18.25 | 13.9 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.33 | 0.34 | 0.34 | 0.36 | 0.37 | |||||
Fixed Assets Turnover | 5.03 | 5.08 | 4.85 | 4.71 | 4.45 | |||||
Receivables Turnover (Average Receivables) | 5.96 | 5.75 | 5.41 | 5.34 | 5.31 | |||||
Inventory Turnover (Average Inventory) | 2.42 | 2.23 | 2.14 | 2.11 | 2.17 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.65 | 1.86 | 2.39 | 2.03 | 1.85 | |||||
Quick Ratio | 1.91 | 1.3 | 1.54 | 1.31 | 1.2 | |||||
Operating Cash Flow to Current Liabilities | 0.73 | 0.59 | 0.67 | 0.63 | 0.55 | |||||
Days Sales Outstanding (Average Receivables) | 62.25 | 63.26 | 67.31 | 68.19 | 68.61 | |||||
Days Outstanding Inventory (Average Inventory) | 153.02 | 162.98 | 169.78 | 172.47 | 167.68 | |||||
Average Days Payable Outstanding | 72.89 | 77.63 | 79.54 | 83.8 | 74.53 | |||||
Cash Conversion Cycle (Average Days) | 142.38 | 148.61 | 157.55 | 156.85 | 161.76 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 53.11 | 47.39 | 49.19 | 51.66 | 61.39 | |||||
Total Debt / Total Capital | 34.69 | 32.15 | 32.97 | 34.06 | 38.04 | |||||
LT Debt/Equity | 52.72 | 39.97 | 48.8 | 49.13 | 55.04 | |||||
Long-Term Debt / Total Capital | 34.44 | 27.12 | 32.71 | 32.4 | 34.1 | |||||
Total Liabilities / Total Assets | 44.56 | 42.05 | 43.19 | 43.97 | 47.36 | |||||
EBIT / Interest Expense | 5.92 | 12.33 | 9.74 | 8.91 | 8.78 | |||||
EBITDA / Interest Expense | 9.11 | 17.7 | 14.84 | 12.97 | 12.91 | |||||
(EBITDA - Capex) / Interest Expense | 7.64 | 15.22 | 12.33 | 10.77 | 10.36 | |||||
Total Debt / EBITDA | 3.25 | 2.55 | 2.94 | 2.79 | 3.15 | |||||
Net Debt / EBITDA | 1.96 | 1.47 | 2 | 1.93 | 2.19 | |||||
Total Debt / (EBITDA - Capex) | 3.88 | 2.97 | 3.53 | 3.36 | 3.92 | |||||
Net Debt / (EBITDA - Capex) | 2.34 | 1.7 | 2.41 | 2.33 | 2.73 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 4.16 | 5.21 | -1.45 | 3.64 | 3.62 | |||||
Gross Profit, 1 Yr. Growth % | 0.6 | 9.88 | -5.12 | 3.24 | 3.09 | |||||
EBITDA, 1 Yr. Growth % | 3.09 | 16.97 | -12.47 | 6.86 | 0.83 | |||||
EBITA, 1 Yr. Growth % | 3.32 | 18.36 | -14.17 | 8.37 | -0.31 | |||||
EBIT, 1 Yr. Growth % | 3.91 | 25.3 | -17.24 | 10.92 | 0.19 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -24.47 | 39.42 | -25.23 | -2.11 | 26.65 | |||||
Net Income, 1 Yr. Growth % | -24.7 | 39.74 | -25.42 | -2.18 | 26.82 | |||||
Normalized Net Income, 1 Yr. Growth % | -9.28 | 48.92 | -7.67 | -2.46 | 0.63 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -24.86 | 40.23 | -24.4 | -2.13 | 30.8 | |||||
Accounts Receivable, 1 Yr. Growth % | 17.59 | 1.63 | 8.05 | 2.17 | 6.32 | |||||
Inventory, 1 Yr. Growth % | 1.99 | 7.03 | 14.67 | -1.44 | 4.96 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.06 | 0.77 | 5.47 | 8.06 | 11.12 | |||||
Total Assets, 1 Yr. Growth % | 2.64 | -2.26 | -0.04 | -1.06 | 1.89 | |||||
Tangible Book Value, 1 Yr. Growth % | 1.3 | -57.14 | 34.97 | -16.49 | 34.6 | |||||
Common Equity, 1 Yr. Growth % | 1.36 | 2.18 | -2.03 | -2.46 | -4.36 | |||||
Cash From Operations, 1 Yr. Growth % | -13.74 | 17.72 | -17.79 | 12.39 | 3.79 | |||||
Capital Expenditures, 1 Yr. Growth % | 11.71 | 0.96 | 6.65 | 8.77 | 17.14 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -45.58 | 5.78 | -22.63 | -46.43 | -22.78 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -43.39 | 0.8 | -20.84 | -44.03 | -20.94 | |||||
Dividend Per Share, 1 Yr. Growth % | 7.41 | 8.62 | 7.94 | 1.47 | 1.45 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -0.72 | 4.69 | 1.83 | 1.06 | 3.63 | |||||
Gross Profit, 2 Yr. CAGR % | -4.11 | 5.14 | 2.11 | -0.89 | 3.17 | |||||
EBITDA, 2 Yr. CAGR % | -6.58 | 10.34 | 1.12 | -2.64 | 5 | |||||
EBITA, 2 Yr. CAGR % | -7.46 | 11.19 | 0.71 | -2.83 | 5.31 | |||||
EBIT, 2 Yr. CAGR % | -9.68 | 14.94 | 1.71 | -3.25 | 7.23 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -11.65 | 2.62 | 2.1 | -14.45 | 11.34 | |||||
Net Income, 2 Yr. CAGR % | -11.76 | 2.58 | 2.09 | -14.59 | 11.38 | |||||
Normalized Net Income, 2 Yr. CAGR % | -12.39 | 16.98 | 15.45 | -4.23 | 2.65 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -11.68 | 2.65 | 2.96 | -13.98 | 13.14 | |||||
Accounts Receivable, 2 Yr. CAGR % | -6.31 | 9.32 | 4.79 | 5.06 | 4.22 | |||||
Inventory, 2 Yr. CAGR % | 7.2 | 4.48 | 10.78 | 6.31 | 1.71 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 24.04 | 4.35 | 3.1 | 6.76 | 9.58 | |||||
Total Assets, 2 Yr. CAGR % | 1.87 | 0.16 | -1.15 | -0.55 | 0.4 | |||||
Tangible Book Value, 2 Yr. CAGR % | -13.52 | -34.11 | -23.94 | 6.17 | 6.02 | |||||
Common Equity, 2 Yr. CAGR % | 1.33 | 1.77 | 0.05 | -2.25 | -3.42 | |||||
Cash From Operations, 2 Yr. CAGR % | -5.63 | 0.77 | -1.62 | -3.88 | 8 | |||||
Capital Expenditures, 2 Yr. CAGR % | 9.31 | 6.2 | 3.77 | 7.71 | 12.88 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 3.57 | -23.99 | -9.58 | 116.52 | -35.34 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -0 | -24.33 | -10.7 | 168.64 | -33.12 | |||||
Dividend Per Share, 2 Yr. CAGR % | 7.7 | 8.01 | 8.28 | 4.65 | 1.46 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 0.18 | 1.22 | 2.6 | 2.43 | 1.91 | |||||
Gross Profit, 3 Yr. CAGR % | -1.87 | 0.34 | 1.6 | 2.49 | 0.42 | |||||
EBITDA, 3 Yr. CAGR % | -3.82 | 0.56 | 2.29 | 3.4 | -1.56 | |||||
EBITA, 3 Yr. CAGR % | -4.64 | 0.31 | 2.16 | 3.66 | -2.07 | |||||
EBIT, 3 Yr. CAGR % | -5.79 | 0.55 | 3.23 | 5.29 | -2.21 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 5.46 | 2.86 | -7.66 | 0.67 | -2.5 | |||||
Net Income, 3 Yr. CAGR % | 5.12 | 2.85 | -7.76 | 0.64 | -2.56 | |||||
Normalized Net Income, 3 Yr. CAGR % | -6.43 | 4.1 | 8.57 | 9.73 | -1.13 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 5.43 | 3.04 | -7.3 | 1.24 | -1.08 | |||||
Accounts Receivable, 3 Yr. CAGR % | -3.01 | -3.73 | 8.89 | 3.91 | 5.48 | |||||
Inventory, 3 Yr. CAGR % | 6.42 | 7.14 | 7.77 | 6.55 | 5.86 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 15.17 | 15.74 | 4.73 | 4.73 | 8.19 | |||||
Total Assets, 3 Yr. CAGR % | 0.61 | 0.48 | 0.1 | -1.12 | 0.26 | |||||
Tangible Book Value, 3 Yr. CAGR % | -9.53 | -31.56 | -16.32 | -21.53 | 14.91 | |||||
Common Equity, 3 Yr. CAGR % | 0.52 | 1.61 | 0.49 | -0.79 | -2.96 | |||||
Cash From Operations, 3 Yr. CAGR % | 10.03 | 1.59 | -5.84 | 2.84 | -1.39 | |||||
Capital Expenditures, 3 Yr. CAGR % | 8.26 | 6.45 | 6.35 | 5.41 | 10.76 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -4.85 | 4.17 | -23.41 | 4.47 | 53.44 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -5.08 | 0.15 | -23.06 | 3.26 | 78.58 | |||||
Dividend Per Share, 3 Yr. CAGR % | 8.03 | 8.01 | 7.99 | 5.96 | 3.57 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 0.88 | 1.3 | 0.84 | 1.16 | 3.01 | |||||
Gross Profit, 5 Yr. CAGR % | -0.17 | 1.19 | -0.3 | -0.21 | 2.23 | |||||
EBITDA, 5 Yr. CAGR % | -0.87 | 1.08 | -1.84 | -0.68 | 3.09 | |||||
EBITA, 5 Yr. CAGR % | -1.05 | 1.12 | -2.49 | -0.89 | 3.1 | |||||
EBIT, 5 Yr. CAGR % | -0.88 | 2.22 | -2.8 | -0.91 | 4.4 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 0.51 | 4.69 | 4.1 | -4.45 | -0.48 | |||||
Net Income, 5 Yr. CAGR % | 0.38 | 4.58 | 3.9 | -4.51 | -0.54 | |||||
Normalized Net Income, 5 Yr. CAGR % | -2.87 | 3.41 | 2.4 | 0.89 | 5.97 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 1.41 | 5.24 | 4.43 | -4.14 | 0.39 | |||||
Accounts Receivable, 5 Yr. CAGR % | -0.36 | -0.14 | 0.04 | -0.3 | 7 | |||||
Inventory, 5 Yr. CAGR % | 4.43 | 6.7 | 8.14 | 6.81 | 5.3 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 5.14 | 7.52 | 10.18 | 12.06 | 6.64 | |||||
Total Assets, 5 Yr. CAGR % | -1.35 | -1.86 | -0.1 | 0.06 | 0.22 | |||||
Tangible Book Value, 5 Yr. CAGR % | -12.72 | -21.33 | -15.6 | -18.42 | -8.01 | |||||
Common Equity, 5 Yr. CAGR % | -0.25 | 0.92 | 0.34 | 0.05 | -1.09 | |||||
Cash From Operations, 5 Yr. CAGR % | 3.64 | 1.32 | 5.21 | -0.64 | -0.53 | |||||
Capital Expenditures, 5 Yr. CAGR % | 5.31 | 1.76 | 6.44 | 6.95 | 8.91 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 0.42 | 17.36 | -6.73 | 4.16 | -13.55 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -0.69 | 12.8 | -7.33 | 1.98 | -13.07 | |||||
Dividend Per Share, 5 Yr. CAGR % | 8.82 | 7.94 | 8.13 | 6.65 | 5.33 |
- Stock Market
- Equities
- MDT Stock
- Financials Medtronic plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition